证券代码：永安药业 证券简称：002365 潜江永安药业股份有限公司 投资者关系活动记录表 编号：2018-04 | --- | --- | --- | --- | --- | |-------------------|--------------------------------|-------|--------------------------------------------------|----------------------------------------------------------------| | | | | | | | | | | | | | | √ | | 特定对象调研 □分析师会议 □媒体采访 | | | 投资者关系 | □ | | 业绩说明会 □新闻发布会 □路演活动 | | | 活动类别 | □ 现场参观 | □其他 | （请文字说明其他活动内容） | | | 参与单位名称 | | | 上海玖歌投资管理有限公司：江龙、孙健 | | | 及人员姓名 | 申万宏源证券：李金显 | | | | | 时间 | 2018 年 6 月 26 日 | | | | | 地点 | ...

证券代码：永安药业 证券简称：002365 潜江永安药业股份有限公司 投资者关系活动记录表 编号：2018-03 | --- | --- | --- | --- | --- | |-------------------------|----------------------------------------------------------------|-------|--------------------------------------------------|------------------------------------------------------------| | | | | | | | | | | | | | | √ | | 特定对象调研 □分析师会议 □媒体采访 | | | 投资者关系 | □ | | 业绩说明会 □新闻发布会 □路演活动 | | | 活动类别 | □ 现场参观 | | □其他 | （请文字说明其他活动内容） | | | 财富证券：潘祥、严正 | | | | | 参与单位名称 及人员姓名 | 金证资本：罗石军 天瑞丰年私募基金：王庆文 | | 广州金控资 ...

证券代码：永安药业 证券简称：002365 潜江永安药业股份有限公司 投资者关系活动记录表 编号：2018-06 | --- | --- | --- | |-------------------------|----------------------------------------------------|----------------------------------------------------------------| | | √ 特定对象调研 □分析师会议 □媒体采访 | | | 投资者关系 | □ 业绩说明会 □新闻发布会 □路演活动 | | | 活动类别 | □ 现场参观 | （请文字说明其他活动内容） | | 参与单位名称 及人员姓名 | 个人投资者：王平、冯刚、王星雨 | | | 时间 | 2018 年 8 月 30 日 | | | 地点 | 公司会议室 | | | 公司接待人员 姓名 | 公司董秘：吴晓波；证代：邓永红 | | | 投资者关系 | 一、公司新建年产 | 万吨牛磺酸项目目前进展情况？ | | 活动主要内容 | | 答：牛磺酸新建产能正在进行带料试车调试，并已出合 ...

Financial Performance - The company's revenue for Q3 2022 was ¥296,215,023.50, a decrease of 28.32% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2022 was ¥45,059,208.86, an increase of 28.07% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥35,453,786.44, up 10.57% from the previous year[5]. - Basic earnings per share for Q3 2022 were ¥0.15, reflecting a 15.38% increase compared to the same period last year[5]. - The company reported a significant increase in net profit for the year-to-date period, up 96.16% to ¥161,651,432.87[5]. - Net profit rose by 72.61% to ¥154,787,504.15, driven by an increase in total profit[9]. - Total profit increased by 80.49% to ¥178,007,501.11, reflecting strong operational performance[9]. - Net profit for the period was CNY 154,787,504.15, an increase of 72.8% compared to CNY 89,676,826.97 in the previous period[24]. - Earnings per share (EPS) for the period was CNY 0.55, up from CNY 0.29 in the previous period[25]. Cash Flow - The operating cash flow net amount for the year-to-date period reached ¥269,339,615.97, a significant increase of 1,936.77%[5]. - Cash flow from operating activities surged by 1936.77% to ¥269,339,615.97, mainly due to increased sales revenue[9]. - The net cash flow from operating activities for the current period is ¥269,339,615.97, a significant increase from ¥13,223,888.88 in the previous period, reflecting a strong operational performance[26]. - Cash inflow from operating activities totaled ¥1,381,813,769.42, compared to ¥1,002,332,853.61 in the previous period, indicating a year-over-year growth of approximately 37.8%[26]. - The cash outflow from operating activities was ¥1,112,474,153.45, up from ¥989,108,964.73, resulting in a net cash flow from operating activities increase of over 1,900%[26]. - The net cash flow from investing activities was -¥250,340,254.71, a decline from a positive cash flow of ¥128,632,637.28 in the previous period, indicating increased investment expenditures[27]. - Total cash inflow from financing activities was ¥31,000,000.00, compared to ¥24,800,000.00 in the previous period, showing a growth of approximately 25%[27]. - The net cash flow from financing activities decreased to -¥10,492,232.43 from -¥140,529,002.14, indicating improved cash management in financing[27]. - The cash and cash equivalents at the end of the period amounted to ¥108,963,400.62, slightly down from ¥111,369,310.81 in the previous period[27]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,364,072,956.00, representing a 3.42% increase from the end of the previous year[5]. - Total assets increased to CNY 2,364,072,956.00, compared to CNY 2,285,925,658.35 in the previous period[22]. - Total liabilities decreased to CNY 240,098,614.08 from CNY 328,946,760.67 in the previous period, a reduction of 27%[22]. - The company's equity attributable to shareholders increased to CNY 2,038,260,282.58, up from CNY 1,865,919,415.64 in the previous period[22]. - Shareholders' equity attributable to the parent company increased by 9.24% to ¥2,038,260,282.58 compared to the end of the previous year[5]. Operational Highlights - The weighted average return on equity for the year-to-date period was 8.28%, an increase of 3.71% compared to the previous year[5]. - Trading financial assets increased by 41.08% to ¥640,532,225.73 due to an increase in wealth management scale[9]. - Accounts receivable decreased by 54.03% to ¥42,281,085.77 primarily due to the maturity of endorsed notes[9]. - Other income rose by 76.44% to ¥5,275,193.12, mainly from increased government subsidies received by subsidiaries[9]. - Research and development expenses were CNY 32,891,798.69, down from CNY 39,209,392.77 in the previous period, indicating a focus on cost management[23]. Investments and Expansion - The company plans to expand its production capacity for taurine food additives by 40,000 tons annually, with an investment of RMB 250 million[13]. - The company provided a guarantee for its subsidiary Hubei Ling'an Technology Co., Ltd. to apply for bank credit of up to RMB 30 million[13]. - A framework agreement was signed with Zhejiang Shuangzi Intelligent Equipment Co., Ltd. for equipment manufacturing and system integration, with a total transaction amount not exceeding RMB 50 million[14]. - Hubei Ling'an Technology Co., Ltd. established a new subsidiary, Hubei Ze'an New Materials Co., Ltd., with a registered capital of RMB 1 million, holding a 50.1% stake[15]. - Hubei Ling'an Technology Co., Ltd. also set up a joint venture, Hubei Ling'an Chemical Co., Ltd., with a registered capital of RMB 1 million, holding a 49% stake[15].

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 826,907,037.44, representing a 16.12% increase compared to CNY 712,125,073.46 in the same period last year[23]. - The net profit attributable to shareholders of the listed company reached CNY 116,592,224.01, a significant increase of 146.88% from CNY 47,225,516.70 in the previous year[23]. - Basic earnings per share rose to CNY 0.40, up 150.00% from CNY 0.16 in the previous year[23]. - The net profit after deducting non-recurring gains and losses was CNY 108,783,673.06, which is an increase of 183.99% from CNY 38,305,102.36 in the same period last year[23]. - The company achieved operating revenue of CNY 826,907,037.44, a year-on-year increase of 16.12%[42]. - The net profit attributable to shareholders reached CNY 116,592,224.01, reflecting a growth of 146.88% compared to the previous year[42]. - The company’s core product, taurine, generated revenue of CNY 636,174,193.96, up 32.76% year-on-year, with net profit increasing by 175.71% to CNY 118,663,117.71[42]. - The company reported a significant increase in other income, which rose to CNY 1,773,278.12 from CNY 1,902,487.61 in the previous year[161]. - The total comprehensive income for the first half of 2022 was CNY 114,104,396.44, up from CNY 51,103,311.38 in the same period of 2021[158]. Cash Flow and Investments - The net cash flow from operating activities was CNY 134,178,943.01, a remarkable turnaround from a negative CNY 29,230,693.90 in the same period last year, marking a 559.03% increase[23]. - The net cash flow from investment activities was CNY -1,666,340.36, a decline of 100.74% compared to the previous period, mainly due to an increase in financial management scale[52]. - The company’s cash flow from operating activities increased by 559.03% to CNY 134,178,943.01, primarily due to increased sales revenue and improved collection of receivables[52]. - The company reported a financial income of CNY 14,752,542.45, compared to a financial expense of CNY 1,452,173.68 in the same period last year, indicating a turnaround[157]. - The total cash inflow from financing activities was CNY 4,000,000.00, while the cash outflow was CNY 73,581,271.02, resulting in a net cash flow of -CNY 69,581,271.02[167]. Market and Industry Insights - The company holds approximately 50% market share in the taurine industry, with an annual production capacity of 58,000 tons, primarily exporting 80% of its products globally[32]. - The demand for taurine in the beverage and health food sectors is rapidly increasing, driven by changing consumer preferences and the rise of e-commerce platforms[31]. - The health food market in China is expanding, influenced by factors such as an aging population and the increasing health consciousness among consumers[35]. - The company anticipates continued growth in the taurine market due to rising demand in various applications, including pet food and aquaculture[31]. - The competitive landscape in the polycarboxylate superplasticizer market is intensifying due to increased production capacity from various companies[33]. Operational Developments - The company is focusing on expanding its product offerings and enhancing its market presence in the health food sector[35]. - The health food subsidiary focuses on the development and sales of functional foods and health products, with existing products including the "Yijianeng" series and "Jianmei" series[38]. - The company is adapting to external challenges such as supply chain disruptions and inflationary pressures while maintaining operational stability[41]. - The company is expanding its taurine production capacity to nearly 100,000 tons per year, following the completion of a 30,000-ton expansion project and plans for an additional 40,000-ton automated production line[45]. Risk Management - The company emphasizes the importance of risk management, including safety, environmental, operational, exchange rate, and management risks[4]. - The company faces safety and environmental risks due to the storage of hazardous chemicals, but has implemented measures such as a 6000m3 emergency pool and automated control systems to mitigate these risks[76]. - The company is exposed to exchange rate risks as a significant portion of its revenue is denominated in USD, which may lead to substantial foreign exchange losses[77]. Legal and Compliance Matters - The company is currently involved in a patent infringement lawsuit in the United States regarding its sulfonic acid products[102]. - The company has been involved in 4 lawsuits related to commercial acceptance bills, with a total amount in dispute of 420,000 yuan for one case and 50,000 yuan for another[103]. - The company has successfully executed a court ruling to recover 420,000 yuan and 32,400 yuan in litigation fees from a previous lawsuit[103]. - The company has reported that it has settled 4 lawsuits, with a total of 775,150 yuan involved in various disputes[103]. Corporate Governance - There were no significant changes in the board of directors, supervisors, or senior management during the reporting period[82]. - The company did not implement any stock incentive plans or employee stock ownership plans during the reporting period[84]. - The company has a total of 500 employees participating in the stock ownership plan, representing 2.58% of the total shares of the listed company[86]. Environmental and Safety Standards - The company’s wastewater treatment facility operates normally, utilizing activated sludge nitrogen removal technology, with a total discharge of 44.5 tons/year for COD and 16.12 tons for ammonia nitrogen[89]. - The company has obtained environmental impact assessment approval for its production lines, including an annual capacity of 58,000 tons of taurine and 40,000 tons of ethylene oxide[90]. - The company has established a safety production management system and conducted 15 safety training sessions and 5 safety skill examinations during the reporting period[93]. Future Outlook - The company plans to expand its market presence and invest in new product development to drive future growth[178]. - The earnings guidance for the second half of 2022 suggests continued growth, with expectations of a revenue increase of approximately 10%[178].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 412,209,105.79, representing a 31.57% increase compared to CNY 313,310,488.45 in the same period last year[4] - Net profit attributable to shareholders reached CNY 50,589,943.61, a significant increase of 544.93% from CNY 7,844,239.23 year-on-year[4] - The net profit after deducting non-recurring gains and losses was CNY 45,936,845.59, up 1,191.12% from CNY 3,557,912.07 in the previous year[4] - Basic earnings per share increased to CNY 0.1649, up 519.92% from CNY 0.0266 in the previous year[4] - The company reported a net profit for Q1 2022 reached CNY 50,083,816.82, a significant increase of 438.73% compared to CNY 9,296,672.16 in Q1 2021[10] - Operating profit surged to CNY 57,757,451.57, reflecting a 454.92% increase from CNY 10,408,203.99 in the previous year, driven by higher sales volume and price increases[10] - Total profit amounting to CNY 57,545,947.50, up 429.66% from CNY 10,864,598.24[10] - The total comprehensive income for the first quarter was CNY 49,907,047.08, up from CNY 9,523,931.09 year-over-year[22] Cash Flow and Assets - The net cash flow from operating activities was CNY 26,157,813.52, a turnaround from a negative CNY 38,850,363.39 in the same period last year, marking a 167.33% improvement[4] - The cash and cash equivalents increased by 93.77% to CNY 181,185,946.20, primarily due to a reduction in financial management scale[9] - The total assets at the end of the reporting period were CNY 2,291,739,822.97, a slight increase of 0.25% from CNY 2,285,925,658.35 at the end of the previous year[4] - The total liabilities decreased from CNY 328,946,760.67 at the beginning of the year to CNY 283,302,217.62 by the end of the first quarter[20] - The accounts receivable rose to CNY 272,806,848.64 from CNY 229,877,761.81 at the beginning of the year[19] - The inventory level remained stable at CNY 145,751,581.05 compared to CNY 145,776,657.54 at the beginning of the year[19] Operating Costs and Expenses - The total operating costs for the first quarter of 2022 amounted to CNY 357,245,810.45, compared to CNY 307,109,062.73 in the previous period[21] - The company incurred a total operating expense of CNY 458,828,129.12, compared to CNY 320,550,716.32 in the same period last year[23] - Financial expenses rose dramatically by 383.17% to CNY 1,048,496.55, attributed to fluctuations in the RMB to USD exchange rate[10] - The company reported a decrease in research and development expenses to CNY 9,935,149.46 from CNY 12,750,543.55 in the previous period[21] Growth and Expansion Plans - The company plans to expand its production capacity for taurine food additives by 40,000 tons annually, with an investment of CNY 250 million from its own funds[14] - The company reported a significant increase in sales volume and unit price as the main reason for the revenue growth[9] Legal and Compliance - The company is actively addressing a patent infringement lawsuit filed in the U.S., indicating a commitment to protecting its intellectual property rights[14] Other Income - The company experienced a 34.46% increase in other income, totaling CNY 1,174,597.07, primarily due to government subsidies received by its subsidiaries[10] - The company recognized government subsidies amounting to CNY 1,174,597.07 related to asset-related government grants during the reporting period[7] Audit Status - The company has not undergone an audit for the first quarter report[25]

Financial Performance - The company's operating revenue for 2021 was ¥1,565,409,181.61, representing a 33.47% increase compared to ¥1,172,853,519.25 in 2020[21] - The net profit attributable to shareholders for 2021 was ¥111,416,036.30, a 5.55% increase from ¥105,559,791.76 in 2020[21] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥91,821,978.42, up 11.26% from ¥82,530,836.12 in 2020[21] - The net cash flow from operating activities decreased by 50.74% to ¥101,810,834.97 from ¥206,662,267.59 in 2020[21] - The total assets at the end of 2021 were ¥2,285,925,658.35, a 5.65% increase from ¥2,163,733,031.71 at the end of 2020[21] - The net assets attributable to shareholders at the end of 2021 were ¥1,865,919,415.64, reflecting a 6.28% increase from ¥1,755,713,012.60 at the end of 2020[21] - The basic earnings per share for 2021 was ¥0.3760, a 2.76% increase from ¥0.3659 in 2020[21] - The diluted earnings per share for 2021 was ¥0.3786, up 3.47% from ¥0.3659 in 2020[21] - The weighted average return on equity for 2021 was 6.16%, a decrease of 0.50% from 6.66% in 2020[21] Market Position and Products - The company holds approximately 50% market share in the global taurine production, with an annual production capacity of 58,000 tons[33] - The company reported a government subsidy of 4.24 million yuan in 2021, down from 10.18 million yuan in 2020[26] - The company has a strong export orientation, with about 80% of its taurine products being exported globally[33] - The demand for taurine in the domestic market is expected to continue growing, particularly in functional beverages and pet food[32] - The company is positioned as a key supplier for major global brands such as Red Bull, Nestlé, and Coca-Cola[33] - The market demand for polycarboxylate superplasticizers is growing at an annual rate of 10% due to the development of high-speed rail projects in China[34] - The company’s taurine products are primarily exported, with 80% of sales directed to international markets[41] Research and Development - The company has applied for 10 patents during the reporting period, including a Japanese invention patent for taurine manufacturing methods[50] - The company has a research and development team with 2 master's degree holders and 3 core technical personnel, holding 26 utility model patents[46] - The company is actively enhancing its brand value and market competitiveness through continuous technological innovation and capacity expansion[49] - The company is currently in the experimental stage of several R&D projects aimed at improving the production efficiency and environmental impact of taurine and other products[79] - The company has completed the development of various functional products, including sports nutrition foods and probiotic preparations, enhancing its market competitiveness[80] Operational Efficiency and Management - The company implemented management reforms to optimize resource allocation and reduce operational costs, enhancing overall efficiency[60] - The company has established a solid online and offline sales model, leveraging partnerships with major e-commerce platforms and live-streaming sales[43] - The company has a strong focus on risk control by assessing customer credit and managing accounts receivable quality[42] - The company has established a comprehensive internal control system to ensure effective governance and risk management, covering all aspects of daily operations[168] - The company has implemented measures to strengthen production and process management to mitigate operational risks[112] Employee and Governance - The company has a total of 6 directors, including 3 independent directors, ensuring compliance with legal requirements[120] - The company has a diverse management team with various roles, including finance and operations, contributing to its strategic direction[143] - The company has implemented a performance-based salary system for directors and senior management, with annual performance assessments determining the remuneration[141] - The company has established a dedicated safety production committee led by the general manager to oversee safety management[194] - The company emphasizes employee welfare, providing various allowances, holiday benefits, and year-end bonuses to enhance overall compensation levels[153] Environmental and Social Responsibility - The company has successfully completed environmental impact assessments for its production lines, including a 58,000-ton taurine production line and a 40,000-ton ethylene oxide production line[181] - The company has implemented a real-time monitoring system for wastewater discharge, ensuring compliance with environmental regulations[180] - The company has invested approximately 19 million yuan in safety production, enhancing its safety measures[191] - Environmental protection investments amounted to about 17.5 million yuan, ensuring compliance with pollution control standards[191] - The company actively engaged in social responsibility initiatives, including participation in job fairs to support rural revitalization[192] Future Outlook - The company plans to expand its production capacity with a project to increase the annual output of taurine food additives by 40,000 tons[145] - The company is focusing on the health food sector, with plans to strengthen its product offerings in sports nutrition and liquid functional beverages[110] - Future outlook includes plans for market expansion and potential mergers and acquisitions to drive growth[135] - The company is actively seeking to transform and expand its business through increased external investments[158]

Financial Performance - The company's revenue for Q3 2021 was CNY 413,233,470.50, representing a 33.26% increase compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2021 was CNY 35,182,276.78, a significant increase of 69.69% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 32,065,703.57, up 146.31% compared to the same period last year[3]. - Basic earnings per share for Q3 2021 were CNY 0.13, an increase of 85.71% year-on-year[3]. - The total operating revenue for the period reached RMB 1,125,358,543.96, an increase of 26.2% compared to RMB 891,403,445.31 in the previous period[22]. - The net profit for Q3 2021 was CNY 89,676,826.97, a decrease of 29.5% compared to CNY 127,276,797.22 in Q3 2020[23]. - Operating profit for Q3 2021 was CNY 100,684,604.67, down 30.6% from CNY 144,995,668.43 in the same period last year[23]. - The total comprehensive income for Q3 2021 was CNY 89,558,557.93, down 29.3% from CNY 126,646,692.12 in Q3 2020[24]. - Basic and diluted earnings per share for Q3 2021 were both CNY 0.29, a decrease from CNY 0.40 in Q3 2020[24]. Cash Flow and Investments - The operating cash flow for the year-to-date period was CNY 13,223,888.88, showing a decrease of 90.21% compared to the previous year[3]. - Net cash flow from operating activities decreased by 90.21% to CNY 13,223,888.88, impacted by rising material prices and shipping costs[10]. - The cash flow from operating activities in Q3 2021 was CNY 13,223,888.88, a significant decrease of 90.2% compared to CNY 135,121,709.95 in Q3 2020[27]. - The total investment cash inflow for Q3 2021 was CNY 756,485,282.76, compared to CNY 628,231,969.39 in Q3 2020, marking an increase of 20.4%[27]. - The net cash flow from financing activities in Q3 2021 was -CNY 140,529,002.14, a decrease from CNY 68,397,257.94 in Q3 2020[28]. - The net cash flow from investing activities decreased by 153.56% to CNY 128,632,637.28, mainly due to a decline in the scale of financial products redeemed[10]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,249,068,923.77, reflecting a 3.94% increase from the end of the previous year[3]. - The company's total assets as of September 30, 2021, were RMB 2,249,068,923.77, compared to RMB 2,163,733,031.71 at the end of 2020[19]. - The company's total liabilities decreased to RMB 328,935,792.31 from RMB 349,924,967.11 in the previous period[20]. - The company's equity attributable to shareholders was CNY 1,829,994,684.89, which is a 4.23% increase compared to the end of the previous year[3]. - The company's equity attributable to shareholders reached RMB 1,829,994,684.89, an increase from RMB 1,755,713,012.60 in the previous period[20]. - Short-term borrowings decreased by 83.65% to CNY 20,000,000.00 as a result of repayment of bank loans[9]. Operational Metrics - Operating costs increased by 33.29% to CNY 815,967,807.25 due to rising raw material prices and increased production and sales volume[9]. - Total profit decreased by 30.91% to CNY 98,623,879.90, primarily due to a reduction in operating profit[9]. - The company reported a 42.18% decrease in income tax expenses to CNY 8,947,052.93, reflecting a decrease in total profit[9]. - Research and development expenses for Q3 2021 amounted to CNY 39,209,392.77, up 21.9% from CNY 32,179,141.38 in Q3 2020[23]. Inventory and Receivables - Accounts receivable increased by 81.61% to CNY 229,017,894.38 due to increased sales and extended collection periods caused by international shipping delays[8]. - Inventory increased by 31.48% to CNY 107,380,288.90 due to preparations for the Double 11 e-commerce promotion[9]. - The company’s inventory increased to RMB 107,380,288.90 from RMB 81,667,741.08 in the previous period[18]. - The company reported a 138.11% increase in prepayments to CNY 56,387,986.98, primarily due to material stocking during holidays[8]. - Other current assets surged by 1057.44% to CNY 8,177,293.36 primarily due to the consolidation of Qian'an Hydrogen Energy and an increase in VAT credits[9]. Investments and Acquisitions - Long-term equity investments rose by 230.94% to CNY 116,726,768.95 as a result of increased investment in Wuhan Low Dimension[9]. - The company acquired 60% of Zhongji Hydrogen Energy for a total price of RMB 36 million, making it a controlling subsidiary[14]. - The company invested RMB 80 million to acquire 40% of Wuhan Low Dimensional, completing the registration of the equity transfer[15]. Legal Matters - The company completed the withdrawal of a patent infringement lawsuit in the U.S., ending the litigation[15].

Financial Performance - The company's operating revenue for the first half of 2021 was ¥712,125,073.46, representing a 22.50% increase compared to ¥581,310,154.14 in the same period last year[19]. - The net profit attributable to shareholders decreased by 49.71% to ¥47,225,516.70 from ¥93,909,650.15 year-on-year[19]. - The net profit after deducting non-recurring gains and losses fell by 56.01% to ¥38,305,102.36 compared to ¥87,070,827.35 in the previous year[19]. - Basic earnings per share decreased by 51.52% to ¥0.16 from ¥0.33 year-on-year[19]. - The company achieved operating revenue of CNY 712,125,073.46, representing a year-on-year growth of 22.50%[38]. - The operating profit reached CNY 56,520,496.48, an increase compared to the same period last year[38]. - The company reported a total revenue of 1,363 million CNY for the first half of 2021, representing a year-on-year increase of 751.1%[62]. - The total revenue for the first half of 2021 reached ¥712.13 million, a 22.5% increase from ¥581.31 million in the same period of 2020[155]. - The total profit for the first half of 2021 was ¥55.97 million, a decline of 50.5% from ¥112.89 million in the same period of 2020[156]. - The comprehensive income for the first half of 2021 totaled ¥51.10 million, down 49.5% from ¥100.98 million in the same period of 2020[157]. Cash Flow and Investments - The net cash flow from operating activities was negative at -¥29,230,693.90, a decline of 143.27% from ¥67,558,751.34 in the same period last year[19]. - The net cash flow from investment activities was 225,419,380.00 CNY, a turnaround from -104,984,576.87 CNY in the previous period, showing improved investment returns[165]. - Cash and cash equivalents at the end of the period totaled 234,769,043.22 CNY, up from 107,672,418.18 CNY, representing a 118.5% increase[166]. - The total cash inflow from investment activities was 558,713,288.59 CNY, compared to 414,376,528.47 CNY in the previous period, reflecting a 34.8% increase[165]. - The company paid 67,870,039.55 CNY to employees, which is an increase of 33.9% from 50,566,594.59 CNY in the previous period[164]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,205,439,950.47, an increase of 1.93% from ¥2,163,733,031.71 at the end of the previous year[19]. - The company's cash and cash equivalents increased to ¥234,769,043.22 from ¥114,196,172.03 at the end of 2020, representing a growth of approximately 105.5%[144]. - The total liabilities decreased from CNY 349,924,967.11 to CNY 331,559,754.25, showing a decline of approximately 5.2%[146]. - Owner's equity totaled CNY 1,873,880,196.22, down from CNY 1,813,808,064.60, indicating a decrease of about 3.3%[148]. - The total liabilities at the end of the period were 1.81 billion, which is a 4.91% increase compared to the previous year[175]. Subsidiaries and Market Position - The company is the largest producer of taurine globally, holding approximately 50% market share, with taurine contributing 361 million CNY, accounting for 50.71% of total revenue[27]. - The company’s subsidiary, Yong'an Health, focuses on the R&D and sales of health and nutritional products, establishing a health industry chain centered around taurine[30]. - The subsidiary Ling'an Technology achieved revenue of 260,158,703.34 yuan, a growth of 36.98%, but its net profit fell by 56.04% to 4,136,943.73 yuan[39]. - Yong'an Health reported revenue of 79,465,620.87 yuan, an increase of 11.77%, while net profit decreased by 67.84% to 2,980,299.12 yuan[40]. Research and Development - Research and development expenses increased by 39.58% to 25,524,165.93 yuan, reflecting a recovery in R&D activities after pandemic-related reductions[46]. - The company obtained 1 new utility model patent for a "quick connector" during the reporting period, enhancing its core competitiveness[41]. - Ling'an Technology established a strong R&D team and obtained 11 new utility model patents, focusing on advanced materials and synthesis processes[42]. Market Trends and Future Plans - The demand for taurine is expected to grow continuously due to its increasing applications in beverages, pet food, and aquaculture feed[31]. - The health food market is seeing a rise in demand for functional foods and dietary supplements, driven by global health trends[30]. - The company plans to strengthen its market position in taurine production by leveraging its production capacity and seeking new business growth points in new energy and new materials[38]. - The company plans to expand its market presence and invest in new product development in the upcoming quarters[172]. Risks and Challenges - The company faces various risks including safety, operational, exchange rate, and management risks[5]. - The polycarboxylate superplasticizer industry faces risks of intensified competition due to increased production capacity from peers[32]. - The company has faced increased operating costs due to rising raw material prices and shipping fees, impacting overall profitability[46]. Corporate Governance and Compliance - The semi-annual financial report has not been audited[92]. - The company has not reported any significant litigation or arbitration matters that would impact its operations[95]. - The company has established a safety production management system and has achieved a secondary level of safety standardization[98]. - The company has implemented an employee stock ownership plan, with a total of 7,988,600 shares allocated at a subscription price of 7.6 yuan per share, which is 80.11% of the average repurchase price[78].

潜江永安药业股份有限公司 2021 年第一季度报告全文 潜江永安药业股份有限公司 2021 年第一季度报告 2021 年 04 月 1 潜江永安药业股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人陈勇、主管会计工作负责人吴晓波及会计机构负责人(会计主管 人员)张天元声明：保证季度报告中财务报表的真实、准确、完整。 2 潜江永安药业股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 313,310,488.45 | 218,568,021.59 | 43.35% | | 归属于上市公司股东的净利润（元） | 7,844,239.23 | 4,943,479 ...